These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38565747)

  • 1. The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Abdelazim K; Allam AA; Afifi B; Abdulazeem H; Elbehiry AI
    Neurol Sci; 2024 Aug; 45(8):3583-3597. PubMed ID: 38565747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
    Qiao Y; Gu J; Yu M; Chi Y; Ma Y
    CNS Drugs; 2024 Mar; 38(3):169-192. PubMed ID: 38429615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
    Qiao Y; Chi Y; Zhang Q; Ma Y
    Front Aging Neurosci; 2023; 15():1169499. PubMed ID: 37213538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of lecanemab for the treatment of Alzheimer's disease: A systematic review.
    Hossain MF; Husna AU; Kharel M
    Brain Behav; 2024 Jun; 14(6):e3592. PubMed ID: 38867460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
    Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
    Honig LS; Sabbagh MN; van Dyck CH; Sperling RA; Hersch S; Matta A; Giorgi L; Gee M; Kanekiyo M; Li D; Purcell D; Dhadda S; Irizarry M; Kramer L
    Alzheimers Res Ther; 2024 May; 16(1):105. PubMed ID: 38730496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease.
    Dhadda S; Kanekiyo M; Li D; Swanson CJ; Irizarry M; Berry S; Kramer LD; Berry DA
    Alzheimers Res Ther; 2022 Dec; 14(1):182. PubMed ID: 36482412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mechanism of action and clinical trial results of Lecanemab (Leqembi
    Niidome T; Ishikawa Y; Ogawa T; Nakagawa M; Nakamura Y
    Nihon Yakurigaku Zasshi; 2024; 159(3):173-181. PubMed ID: 38692883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis.
    Jeremic D; Navarro-López JD; Jiménez-Díaz L
    Ageing Res Rev; 2023 Sep; 90():102012. PubMed ID: 37423541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
    McDade E; Cummings JL; Dhadda S; Swanson CJ; Reyderman L; Kanekiyo M; Koyama A; Irizarry M; Kramer LD; Bateman RJ
    Alzheimers Res Ther; 2022 Dec; 14(1):191. PubMed ID: 36544184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis.
    Ebell MH; Barry HC; Baduni K; Grasso G
    Ann Fam Med; 2024; 22(1):50-62. PubMed ID: 38253509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
    Terao I; Kodama W
    Ageing Res Rev; 2024 Feb; 94():102203. PubMed ID: 38253184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease.
    Cohen S; van Dyck CH; Gee M; Doherty T; Kanekiyo M; Dhadda S; Li D; Hersch S; Irizarry M; Kramer LD
    J Prev Alzheimers Dis; 2023; 10(4):771-777. PubMed ID: 37874099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling lecanemab as a treatment option for Alzheimer's disease.
    Schiller ER; Silverglate BD; Grossberg GT
    Expert Rev Neurother; 2024 May; 24(5):433-441. PubMed ID: 38566584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
    Wang D; Kowalewski EK; Koch G
    Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lecanemab: Appropriate Use Recommendations.
    Cummings J; Apostolova L; Rabinovici GD; Atri A; Aisen P; Greenberg S; Hendrix S; Selkoe D; Weiner M; Petersen RC; Salloway S
    J Prev Alzheimers Dis; 2023; 10(3):362-377. PubMed ID: 37357276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.